BoxX-NoAF Clinical Trial
← catalyst calendarNCT06989775 · readout ≤ 193 d
Sponsored by AtriCure, Inc. (industry) · ATRC — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
960estimated
Sites
27
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-24 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Post Operative Atrial Fibrillation
- Atrial Fibrillation, Postoperative
Intervention
- Device: Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System
Primary outcomes
what the primary-completion date above is the date OFPrimary Effectiveness Endpoint
measured 30 days post index cardiac surgical procedure
Primary Safety Endpoint
measured 30 days post index cardiac surgical procedure
Permalink · ATRC's whole pipeline · Catalyst calendar · Every registered study · What changed